LUYE PHARMA GROUP LTD

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

Related tickers: LPCN, BRIBY, GHRS, JNJ, CMPS, ATAI, SAGE, LYPHF, AXSM, RLMD.

The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.

Related tickers: RVPH, RVPHW, VNDA, LYPHF.